I am a
Home I AM A Search Login

Papers of the Week

Papers: 26 Nov 2022 - 2 Dec 2022

2022 Nov 25

Int Immunopharmacol


Blocking Cx43 alleviates neuropathic pain in rats with chronic constriction injury via the P2X4 and P38/ERK-P65 pathways.


Xing J, Wang Η, Chen L, Wang H, Huang H, Huang J, Xu C
Int Immunopharmacol. 2022 Nov 25; 114:109506.
PMID: 36442284.


Neuropathic pain is a growing concern in the medical community, and studies on new analgesic targets for neuropathic pain have become a new hot spot. Whether Connexin43 (Cx43) has a key role in neuropathic pain mediated by the purinergic 2X4 (P2X4) receptor in rats with chronic constriction injury (CCI) was explored in this study. Our experimental results show that blockade of Cx43 could attenuate neuropathic pain in rats suffering from CCI via the P2X4, p38, ERK, and NF-kB signalling pathways. These results suggest that Cx43 may be a promising therapeutic target for the development of novel pharmacological agents in the management of neuropathic pain.